Glen Harbor Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Glen Harbor Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$397K	Sell	4,048 -272	-6%	-$30.7K	0.01%	782
2019 Q2	$566K	Sell	4,320 -1,472	-25%	-$190K	0.01%	669
2019 Q1	$783K	Buy	5,792 +1,424	+33%	+$177K	0.02%	516
2018 Q4	$425K	Sell	4,368 -80	-2%	-$9.46K	0.01%	682
2018 Q3	$618K	Buy	4,448 +48	+1%	+$6.02K	0.01%	630
2018 Q2	$546K	Buy	4,400 +592	+16%	+$69.2K	0.01%	615
2018 Q1	$424K	Sell	3,808 -160	-4%	-$19.1K	0.01%	699
2017 Q4	$475K	Buy	3,968 +1,104	+39%	+$134K	0.01%	659
2017 Q3	$402K	Sell	2,864 -512	-15%	-$69.6K	0.01%	663
2017 Q2	$411K	Buy	3,376 +272	+9%	+$31.7K	0.01%	646
2017 Q1	$376K	Buy	3,104 +480	+18%	+$61.9K	0.01%	624
2016 Q4	$321K	Buy	+2,624	New	+$321K	0.01%	608

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Glen Harbor Capital Management's ALXN Position: Q3 2019 in Review

Glen Harbor Capital Management reduced its Alexion Pharmaceuticals (ALXN) stake by 6.3% in Q3 2019, selling an estimated $30.7K and leaving 4,048 shares worth $397K. The position accounts for 0.01% of the portfolio, ranked #782.

Glen Harbor Capital Management first reported a position in ALXN in Q4 2016 and has held it in 12 quarters since. The position peaked at $783K in Q1 2019. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

Glen Harbor Capital Management held 4,048 shares of Alexion Pharmaceuticals worth $397K as of Q3 2019.
Glen Harbor Capital Management sold 272 Alexion Pharmaceuticals shares in Q3 2019, an estimated $30.7K.
Alexion Pharmaceuticals made up 0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #782 holding.
Glen Harbor Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
Glen Harbor Capital Management's Alexion Pharmaceuticals position peaked at $783K in Q1 2019.
647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.